{"id":"NCT01235507","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)","officialTitle":"Actemra - Local Bosnian Open, Multicentric, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis After Inadequate Response to DMARDs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2010-11-05","resultsPosted":"2014-10-20","lastUpdate":"2014-11-07"},"enrollment":71,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"methotrexate","otherNames":[]},{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"Single Arm","type":"EXPERIMENTAL"}],"summary":"This open-label, single arm study will assess the safety and efficacy of RoActem ra/Actemra (tocilizumab) in combination with methotrexate in patients with activ e moderate to severe rheumatoid arthritis who have an inadequate response to dis ease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Act emra at a dose of 8 mg/kg (maximum 800 mg) intravenously every 4 weeks for a tot al of 6 infusions. Methotrexate will be continued at a stable dose. Anticipated time on study treatment is 24 weeks.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)","timeFrame":"Screening Visit, Baseline, Weeks 4, 8, 12, 16, 20 and 24","effectByArm":[{"arm":"Tocilizumab Plus MTX","deltaMin":14.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":3,"countries":["Bosnia and Herzegovina"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":71},"commonTop":["Leukocytopenia","Elevated AST","Thrombocytopenia"]}}